Naftopidil
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- active pharmaceutical ingredient, api, naftopidil
- Category
- Other Pharmaceuticals
Inist ST
South Korea
- Verified Certificate
-
16
| Product name | Naftopidil | Certification | - |
|---|---|---|---|
| Category | Other Pharmaceuticals | Ingredients | - |
| Keyword | active pharmaceutical ingredient , api , naftopidil | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | - |
| Supply type | - | HS code | - |
Product Information
Naftopidil
| Category |
Prostatitis
| Spec |
JP / IHS
| Description |
Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.
It is a drug used in benign prostatic hypertrophy which acts as a selective α1-adrenergic receptor antagonist or alpha blocker.
An enlarged prostate (called benign prostatic hyperplasia) can cause bothersome lower urinary tract symptoms such as having to urinate often during the day or at night, having a weak urine stream, and having the feeling of not emptying the bladder completely. A common reason for these complaints is an enlarged prostate, which is common in older men. Naftopidil is a medication that may help with these symptoms and possibly cause fewer unwanted effects than other medications used for this problem.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Kim Kuk-hyun
- Address
- Geumwang-Eup, 500 Shinaero , Eumseong-gun, Chungcheongbuk-do, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 2000
- Company introduction
-
Having persistent enthusiasm, INIST ST is trying to contribute to the society and community by delivering healthier life from age 0 to 110 years through research and innovation. Since its establishment in 2000, INIST ST has been accomplishing rapid growth with passion, confidence and trust between customers and the company. INIST ST has developed non-cytotoxic anti-cancer, high quality generic & value-added API and supplied to the domestic and overseas markets. INIST ST has intensive R&D function in exploration of drug candidate and process development of small molecules. As result of those efforts, INIST ST has achieved multiple crystal and process patents and become partner of several government sponsoring development projects.
- Main Markets
-
Japan
Taiwan
Turkey
U.S.A
- Main Product
Related Products
Botalinum Ampoule
LIPONEX PPC Injection
G2ON Synbiotics Lactobacillus Probiotics
Mumus Guard Plus Mosquito Repellent for All Family Members
Liporase injection
